ORPEA

Earnings Release • Feb 9, 2010

PRESS RELEASE

2009 annual sales up sharply: +20.1% to €843.2 million Strong organic growth, at +11.1% 2010 prospects: strong growth, solid profitability and value-creating development

Puteaux, 9th February 2010

ORPEA, a leading player in Long-Term Care (nursing homes), Post-Acute Care and Psychiatric Care, today announced its full-year 2009 sales to 31st December.

In €m	Annual			Quaterly
IFRS	2009	2008	Δ	Q4 2009	Q4 2008	Δ
France	738.3	613.1	+20.4%	195.6	162.5	+20.4%
% of total sales	88%	87%		88%	85%
International	104.9	89.2	+17.6%	26.4	26.3	+0.3% *
% of total sales	12%	13%		12%	15%
Belgium	48.4	38.3		12.4	12.1
Spain	28.7	27.2		7.3	7.3
Italy	17.9	15.4		4.2 *	4.5
Switzerland	9.9	8.3		2.5	2.3
Total sales	843.2	702.3	+20.1%	222.0	188.8	+17.6%
Organic growth			+11.1%			+10.9%

* Taking into account the divestment of a facility in Italy in 2009

Yves Le Masne, Deputy CEO, commented: "In 2009, ORPEA again recorded very strong growth in activity, notably with organic growth that remained very strong at over 11%.

Over the entire year, sales were up by +20% and totalled €843.2 million, or €23.2 million more than the initial guidance given at the start of the year.

The recurrence of buoyant organic growth, which has exceeded 10% for a number of years, is a result of the policy implemented by ORPEA that aims to permanently optimise all of its facilities' Quality factors: improvement in medical and paramedical care through the continuous training of its teams, modernisation of infrastructures, equipment and technical platforms, pursuit of innovative concepts, thought regarding architecture, etc. All of the latter increase the appeal of the Group's facilities, and explain the permanently very high recommendation rate of our facilities by both residents and their families (93.6% over the last two years)."

Doctor Jean-Claude Marian, Chairman and CEO, adds: "On 10th March, we will publish an update on the Group's development and, as is customary, will issue our sales guidance for FY 2010. Moreover, ORPEA will be revising up its sales target for 2011.

Given how well all our indicators are holding up, in early 2010, and the satisfactory progress being made on facilities due to open this year, ORPEA is already anticipating another year of dynamic growth, accompanied by solid profitability. In a sector that continues to offer considerable potential, ORPEA, backed by the further financial means arranged in 2009 (€217 million OBSAAR bond issue and €62.5 million capital increase), will pursue its value-creating process through the implementation of further authorisations and the continuation of its selective acquisition policy.

Given the sector's exceptional visibility, ORPEA's intrinsic qualities and the 8,500 beds currently being renovated or under construction, the profitable growth and development momentum is of course amply guaranteed well beyond 2010."

• First-half 2010 financial agenda

The dates given below are indicative only. Press releases will be published before the market opens.

Event	Date
Update on development and 2010 sales target	Wednesday 10th March 2010
2009 Full-year results	Wednesday 31st March 2010
2010 Q1 sales	Wednesday 5th May 2010
2010 H1 sales	Wednesday 21st July 2010

About ORPEA (www.orpea.com): Listed on Euronext Paris since April 2002 and recently promoted to the Deferred Settlement Service, the ORPEA group is a leading player in the Long-Term Care and Post-Acute Care sectors. As of September 2009, the Group has a unique European network of healthcare facilities, with 26,526 beds (21,565 of them operational) across 284 sites, including:

• 21,585 beds in France: 17,619 operational (including 3,021 being renovated) + 3,966 under construction, spread across 238 sites.
• 4,941 beds in Europe (Spain, Belgium, Italy and Switzerland): 3,946 operational (including 508 being renovated) + 995 under construction, spread across 46 sites.

Listed on Euronext Paris Compartment A of NYSE Euronext - ISIN: FR0000184798 Member of the SBF 120 index and SRD Reuters: ORP.PA - Bloomberg: ORP FP

Investor Relations

NewCap. ORPEA Emmanuel Huynh/Steve Grobet Yves Le Masne Tel: +33 (0)1 44 71 94 94 Deputy CEO orpea@newcap.fr Tel: +33 (0)1 47 75 78 07